SCHEMBL21298846

SCHEMBL21298846

CC(C)C1CC(=O)N(C(C)(C)C)C1O

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21163130 0.83
SCHEMBL20683211 0.75 MEN1 (0.32) MAPT
SCHEMBL22606192 0.73 MAPT (0.35) MAPT
SCHEMBL21972869 0.73 POLB (0.34) POLB
SCHEMBL10160139 0.72 POLB (0.32) POLB
SCHEMBL18134951 0.69 POLB (0.32) POLB
SCHEMBL21887534 0.66 MAPT (0.30) MAPT
SCHEMBL10211148 0.65 POLB (0.35) POLBMAPT
SCHEMBL1106105 0.64 MAPT (0.31) POLBMAPT
SCHEMBL10103000 0.64 MAPT (0.31) POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392421-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2019-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392421-B2 Cytotoxic peptides and conjugates thereof CD47, NGLY1, VIP POLB 3250/4885MAPT 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.